Welcome to Junho Chung's Laboratory



Therapeutic antibody development


We focus on the development of clinically available therapeutic antibodies. An anti-HGF antibody (NOV1105) is now in phase I clinical trial (ClinicalTrials.gov Identifier: NCT02499224, Safety and Pharmacokinetics Study of YYB101 in Advanced Solid Tumors Patients Who Are Refractory to Standard Therapy). We are also developing anti-complement C5 antibody in collaboration with Celltrion, Inc (www.celltrion.com). Several other antibodies are under lead development stage, which includes SFTSV (severe fever with thrombocytopenia syndrome virus) neutralizing antibody, MERSV (middle east respiratory syndrome virus) neutralizing antibody, anti-PDGFRbeta antibody and anti-CD40L X CD28 bispecific antibody). An editorial describing the current status of therapeutic antibodies is available (Chung J. Special issue on therapeutic antibodies and biopharmaceuticals. Exp Mol Med. 2017 Mar 24;49(3):e304. PubMed PMID: 28336954; PubMed Central PMCID: PMC5382567).


Bridging antibodies and chemicals with cotinine


We developed an high affinity anti-cotinine antibody. Cotinine is major metabolite of nicotine, to which human has long been exposed via smoking. It is physiologically absent, phamacologically inert and very safe inside human body. Cotinine and anti-cotinine antibody works like biotin-avidin pair. Antibodies or proteins fused with anti-cotinine scFv can be complexed with any cotinine-conjugated chemcials. A review about possible application of this system is available as an open access article (BMB Rep. 2014 Mar; 47(3): 130–134. PMID: 24499668 doi:  10.5483/BMBRep.2014.47.3.006).


Development of new platform technology for antibody engineering


We are engineering antibodies for providing new characters to the molecule, which includes replacing residues with cystine useful for site-directed conjugation of chemical like radioisotope, cytotoxic drugs, etc.


Department of Biochemistry and Molecular Biology, Seoul National University College of Medicine

Department of Biomedical Sciences, Seoul National University College of Medicine

Laboratory of Antibody Engineering, Cancer Research Institute, Seoul National University



Suites 506-515, Samsung Cancer Research Building

Daehakro 103, Seoul 03080, South Korea (Rep. of Korea)


Last update: 13  May 2017